文献速递特殊人群用药肝肾功能剂量调整

NAT2与YEATS4药物基因组学结果反馈的随机对照子研究:GUARDD-US PGx研究

A Pilot Randomized Study of NAT2 and YEATS4 Pharmacogenetic Return of Results in Adults with Hypertension and African Ancestry: The GUARDD-US PGx Study.
PubMed 文献 · Clin Pharmacol Ther · 2026-10-18

该多中心随机对照子研究纳入1874例自报非洲裔高血压患者,比较即时与延迟反馈NAT2和YEATS4药物基因组学结果对3个月收缩压的影响。整体人群未见收缩压改善,但携带有可操作YEATS4基因型或基线血压未控制者,即时反馈组收缩压下降更显著。

要点

  • 整体高血压人群即时反馈药物基因组学结果未显著改善3个月收缩压。
  • 可操作YEATS4基因型者即时反馈组收缩压多降2.46 mmHg(95%CI -4.57至-0.36)。
  • 基线未控制高血压者即时反馈组收缩压多降2.9 mmHg(95%CI -5.6至-0.3)。

核心结论

  • 在整体高血压成人中,即时反馈NAT2和YEATS4药物基因组学结果未改善3个月收缩压。
  • 在可操作YEATS4基因型或基线未控制高血压的亚组中,即时反馈与更大幅度的收缩压下降相关。

研究设计与样本

  • 多中心随机对照子研究,纳入1874例自报非洲裔高血压患者。
  • 参与者随机分为即时药物基因组学结果反馈组(干预)和试验结束时延迟反馈组(对照)。
  • 通过临床决策支持传达YEATS4指导的噻嗪类利尿剂选择和NAT2指导的肼屈嗪剂量建议。

主要发现

  • 整体人群中,两组3个月收缩压变化无显著差异(协变量校正后组间差值-0.3±0.74 mmHg,95%CI -1.8至1.2)。
  • 可操作YEATS4基因型者(N=867)中,即时反馈组3个月收缩压多降2.46 mmHg(95%CI -4.57至-0.36)。
  • 基线未控制高血压者(N=659)中,即时反馈组收缩压多降2.9±0.74 mmHg(95%CI -5.6至-0.3)。

临床怎么用

  • 对高血压患者开展YEATS4药物基因组学检测,识别可操作基因型以指导噻嗪类利尿剂选择可能获益。
  • 优先对基线血压未控制的高血压患者实施药物基因组学结果反馈。
  • NAT2指导的肼屈嗪剂量建议在整体人群中未显著改善收缩压,需结合临床判断使用。

局限性

  • 研究为试点子研究,随访仅3个月,长期效果未评估。
  • 整体人群包含血压已控制者,可能稀释干预效果。
  • 仅纳入自报非洲裔人群,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Almost half of individuals with hypertension fail to achieve recommended blood pressure (BP) goals. Pharmacogenetic gene-drug interactions may alter the efficacy of antihypertensive agents. We conducted a multicenter randomized controlled sub-study of participants (N = 1874) with hypertension and self-reported African ancestry to determine whether pharmacogenetic return of results (RoR) would improve systolic blood pressure (SBP) at 3 months. Participants were randomized to immediate pharmacogenetic RoR (intervention) or delayed RoR at trial completion (control). Clinical decision support conveyed recommendations for YEATS4-guided thiazide diuretic selection and NAT2-guided hydralazine dosing. Prespecified subgroup analyses included those with uncontrolled BP (baseline SBP ≥140 or DBP ≥90 mm Hg) and actionable genotypes. Immediate RoR did not improve SBP at 3 months in a broad population of hypertensive adults with controlled and uncontrolled SBP (covariate-adjusted change in SBP between groups: -0.3 ± 0.74 mm Hg, 95% CI: -1.8, 1.2). In participants with an actionable YEATS4 genotype (N = 867) predicting reduced thiazide efficacy, immediate RoR led to greater SBP reduction at 3 months (-2.46 mm Hg, 95% CI: -4.57 to -0.36). In participants with uncontrolled hypertension at baseline (N = 659), immediate RoR led to a greater reduction in SBP (-2.9 ± 0.74 mm Hg, 95% CI: -5.6, -0.3). Although no SBP reduction was observed in the whole cohort, participants with an actionable YEATS4 genotype or uncontrolled BP who received immediate RoR had a significantly greater SBP improvement than those with delayed RoR. Future studies of antihypertensive pharmacogenetics should recruit individuals with uncontrolled BP and actionable genotypes.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Empey PE, Limdi NA, Mohottige D, et al. A Pilot Randomized Study of NAT2 and YEATS4 Pharmacogenetic Return of Results in Adults with Hypertension and African Ancestry: The GUARDD-US PGx Study. Clin Pharmacol Ther. 2026. PMID: 42894271. doi:10.1002/cpt.70527

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。